Category Archives: Government

FDA goes on a rulings binge

      No Comments on FDA goes on a rulings binge

FDA ROUNDUP: In one of the busiest rulings binges of the year, the US Food and Drug Administration last week approved an assortment of pharmaceuticals, medical devices, an AI algorithm… Read more »

Health-sector stocks mostly up after nerve-racking presidential debate.

Winners barely beat out losers last week as health care outshone climate change and gun control (among other topics) at the latest Democratic debate last week. (See our broader health-sector… Read more »

All three of the world’s major drug regulators have busy week despite heat waves, political chaos. You know; the usual.

Last week was a rare case where the world’s leading drugs and devices regulators were all in action simultaneously. The US Food and Drug Administration (FDA), the European Medicines Agency… Read more »

European drug regulator comes out of hibernation in new Dutch headquarters, rivaling the FDA with rulings; well, just for one week.

It may have taken nearly 6 months and perhaps a Fourth of July holiday-shortened work week here in the US, but the European Medicines Agency (EMA) finally issued some new… Read more »

Brexit referendum slowing the European Medicines Agency’s operations to a crawl.

The News: The European Medicines Agency (EMA) recently addressed its concerns for ensuring business continuity and staff retention which had become huge challenges caused by the Brexit referendum. The EMA… Read more »

Medical Stock Spotlight: Three winners from last week hit with profit-taking, while one big loser rebounds. This week, Provention shines, but Cymabay bombs.

Stocks continue to be whipsawed by sudden upward, then plunging, prices, only to reverse direction again as political and economic uncertainty reigns supreme. Here are four prime examples of this… Read more »

The worldwide battle over health spending, especially high drug prices, and whether it’s actually worth it. The view from afar.

Commentary: Steve Walker The “Medicare for All” plan embraced by leading 2020 Democrats looks more lavish than what other advanced countries offer, compounding the cost but also potentially broadening its… Read more »